
On July 17, 2023, the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV in infants and children up to 24 months...

According to Moderna, at 3.7 months following administration, MRESVIA RSV vaccine efficacy was reported to be 78.7 percent against RSV illness with two or more symptoms of lower respiratory tract...

According to GSK, AREXVY RSV vaccine efficacy was reported to be 82.6 percent against the first occurrence of RSV related lower respiratory tract infection in persons 60 through 79 years...

Pfizer reports that the vaccine efficacy in infants born from mothers who received the RSV vaccine during the third trimester of pregnancy was 57.1 percent at 90 days after birth,...

In the pre-licensing clinical trial, Pfizer reported vaccine efficacy to be 66.7 percent against the first episode of RSV-related lower respiratory tract infection with two or more symptoms, and had...

On July 17, 2023 the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV. Though the CDC has determined that it...

On May 31, 2024, the FDA approved MRESVIA, an mRNA RSV vaccine manufactured by Moderna, for use in persons 60 years of age and older. The approval of MRESVIA was...

In August 2022, Pfizer issued a press release announcing the success of their Phase 3 clinical trial of a bivalent RSV prefusion F vaccine candidate, RSVpreF, in persons 60 years...

In October 2022, GlaxoSmithKline (GSK) pharmaceutical issued a press release that reported their RSV vaccine reduced severe RSV illness by 94.1 percent in persons 60 years and older. GSK also...

Get answers about vaccine education in the classroom and how to inspect school curriculum and opting your child out of lessons.